• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国阿尔茨海默病的经济影响。非住院阿尔茨海默病患者的护理成本和疾病严重程度。

Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.

作者信息

Souêtre E, Thwaites R M, Yeardley H L

机构信息

Pharmacoeconomic Research, Glaxo Wellcome Research & Development, Middlesex, UK.

出版信息

Br J Psychiatry. 1999 Jan;174:51-5. doi: 10.1192/bjp.174.1.51.

DOI:10.1192/bjp.174.1.51
PMID:10211151
Abstract

BACKGROUND

While the costs associated with Alzheimer's disease have been shown to be significant, there are few data relating cost of care to severity of the disease.

AIMS

We aimed to compare the costs associated with different severities of Alzheimer's disease with those incurred by control subjects over a three-month period.

METHOD

In this cross-sectional, multicentre, naturalistic analysis, non-institutionalised patients with Alzheimer's disease (128), their care-givers (128), and 56 matched controls were interviewed once to establish resource use over the previous three months. Patients were stratified into three severity groups according to their Mini Mental State Examination score. Costs were calculated from the perspective of society as a whole.

RESULTS

Over the three-month period, total mean cost per control subject (387 Pounds) was minor compared with mean cost incurred by patients with mild (6616 Pounds), moderate (10,250 Pounds) and severe (13,593 Pounds) Alzheimer's disease. Indirect cost, mainly time spent by care-givers, was the main cost component in all groups (68.6%), followed by direct medical costs (24.7%).

CONCLUSIONS

The cost of care for an Alzheimer's disease patient is directly related to the severity of the patients illness.

摘要

背景

虽然已证明与阿尔茨海默病相关的费用很高,但很少有数据将护理成本与疾病严重程度联系起来。

目的

我们旨在比较阿尔茨海默病不同严重程度患者与对照组在三个月期间产生的费用。

方法

在这项横断面、多中心、自然主义分析中,对非机构化的阿尔茨海默病患者(128例)、他们的护理人员(128例)以及56名匹配的对照组进行了一次访谈,以确定前三个月的资源使用情况。根据简易精神状态检查表得分将患者分为三个严重程度组。从整个社会的角度计算费用。

结果

在三个月期间,每个对照组的平均总费用(387英镑)与轻度(6616英镑)、中度(10250英镑)和重度(13593英镑)阿尔茨海默病患者产生的平均费用相比微不足道。间接成本,主要是护理人员花费的时间,是所有组中的主要成本组成部分(68.6%),其次是直接医疗成本(24.7%)。

结论

阿尔茨海默病患者的护理成本与患者疾病的严重程度直接相关。

相似文献

1
Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.英国阿尔茨海默病的经济影响。非住院阿尔茨海默病患者的护理成本和疾病严重程度。
Br J Psychiatry. 1999 Jan;174:51-5. doi: 10.1192/bjp.174.1.51.
2
Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.非机构化阿尔茨海默病患者的资源利用、成本及临床结局:英国GERAS观察性研究的18个月结果
BMC Geriatr. 2016 Nov 25;16(1):195. doi: 10.1186/s12877-016-0371-6.
3
Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.意大利阿尔茨海默病的成本和资源利用:一项观察性研究的结果。
J Prev Alzheimers Dis. 2018;5(1):55-64. doi: 10.14283/jpad.2017.31.
4
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.法国阿尔茨海默病的资源使用与成本:GERAS观察性研究的18个月结果
Value Health. 2018 Mar;21(3):295-303. doi: 10.1016/j.jval.2017.09.019. Epub 2017 Nov 11.
5
Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.阿尔茨海默病连续体中的依赖程度作为临时临床里程碑:来自 GERAS 观察性研究的 18 个月结果。
J Prev Alzheimers Dis. 2017;4(2):72-80. doi: 10.14283/jpad.2017.2.
6
The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.GERAS 研究:在三个欧洲国家的社区居住的阿尔茨海默病患者中成本和资源利用的前瞻性观察研究——研究设计和基线结果。
J Alzheimers Dis. 2013;36(2):385-99. doi: 10.3233/JAD-122392.
7
Increase in direct social care costs of Alzheimer's disease in Japan depending on dementia severity.日本阿尔茨海默病的直接社会护理费用随痴呆严重程度的增加而增加。
Geriatr Gerontol Int. 2019 Oct;19(10):1023-1029. doi: 10.1111/ggi.13764. Epub 2019 Sep 2.
8
Relation between severity of Alzheimer's disease and costs of caring.阿尔茨海默病严重程度与护理成本之间的关系。
CMAJ. 1998 Sep 8;159(5):457-65.
9
Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.轻度至中度阿尔茨海默病临床试验样本中的护理成本:关键资源及其决定因素。
Alzheimers Dement. 2011 Jul;7(4):466-73. doi: 10.1016/j.jalz.2010.06.002.
10
Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.美国早期阿尔茨海默病的成本:一项前瞻性队列研究(GERAS-US)的横断面分析 1 。
J Alzheimers Dis. 2020;75(2):437-450. doi: 10.3233/JAD-191212.

引用本文的文献

1
Comparative study of F-labeled PET radiopharmaceuticals in an Alzheimer's disease mouse model.F 标记的正电子发射断层显像(PET)放射性药物在阿尔茨海默病小鼠模型中的比较研究。
BMC Neurosci. 2025 Aug 28;26(1):55. doi: 10.1186/s12868-025-00978-0.
2
The Costs of Dementia in Europe: An Updated Review and Meta-analysis.欧洲的痴呆症成本:一项更新的综述和荟萃分析。
Pharmacoeconomics. 2023 Jan;41(1):59-75. doi: 10.1007/s40273-022-01212-z. Epub 2022 Nov 15.
3
Trends, Predictors, and Outcomes of Healthcare Resources Used in Patients Hospitalized with Alzheimer's Disease with at Least One Procedure: The Nationwide Inpatient Sample.
患有阿尔茨海默病且至少接受过一次手术的住院患者医疗资源使用的趋势、预测因素及结果:全国住院患者样本
J Alzheimers Dis. 2017;57(3):813-824. doi: 10.3233/JAD-161225.
4
Comparison of informal care time and costs in different age-related dementias: a review.不同年龄相关性痴呆症的非正规护理时间和成本比较:综述。
Biomed Res Int. 2013;2013:852368. doi: 10.1155/2013/852368. Epub 2012 Dec 5.
5
A pharmacy led program to review anti-psychotic prescribing for people with dementia.药房主导的项目,旨在审查治疗痴呆患者的抗精神病药物处方。
BMC Psychiatry. 2012 Sep 25;12:155. doi: 10.1186/1471-244X-12-155.
6
Cost of Alzheimer's disease.阿尔茨海默病的成本。
Dialogues Clin Neurosci. 2000 Jun;2(2):157-61. doi: 10.31887/DCNS.2000.2.2/mdavidson.
7
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.中重度阿尔茨海默病认知增强剂的药物经济学。
CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.
8
Alzheimer's disease: the strength of association of costs with different measures of disease severity.阿尔茨海默病:成本与不同疾病严重程度衡量指标之间关联的强度。
J Nutr Health Aging. 2010 Oct;14(8):655-63. doi: 10.1007/s12603-010-0312-6.
9
The cost of dementia in Europe: a review of the evidence, and methodological considerations.欧洲痴呆症的成本:证据综述及方法学考量
Pharmacoeconomics. 2009;27(5):391-403. doi: 10.2165/00019053-200927050-00004.
10
Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.法国、德国和意大利湿性年龄相关性黄斑变性患者的视力与医疗及非医疗费用之间的关联
Drugs Aging. 2008;25(3):255-68. doi: 10.2165/00002512-200825030-00007.